TY - JOUR
T1 - Development of plasma ghrelin level as a novel marker for gastric mucosal atrophy after Helicobacter pylori eradication
AU - Mori, Hideki
AU - Suzuki, Hidekazu
AU - Matsuzaki, Juntaro
AU - Kameyama, Kaori
AU - Igarashi, Koji
AU - Masaoka, Tatsuhiro
AU - Kanai, Takanori
N1 - Funding Information:
During the last 2 years, H.S. received scholarship funds from Astellas Pharm, Inc., Astra-Zeneca K.K., Otsuka Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., and Zeria Pharmaceutical Co., Ltd., joint research fund from Tosoh Corporation and service honoraria from Astellas Pharm, Inc., Astra-Zeneca K.K., EA Pharma Co., Otsuka Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Tsumura Co. and Zeria Pharmaceutical Co., Ltd. T.K. received scholarship funds from Astellas Pharm, Inc., Astra-Zeneca K.K., Otsuka Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Eisai Pharmaceutical Co., Ltd., Zeria Pharmaceutical Co., Ltd., Tanabe Mitsubishi Pharmaceutical Co., Ltd., JIMRO Co., Ltd., and Kyorin Pharmaceutical Co., Ltd., and service honoraria from Astellas Pharm, Inc., Eisai Pharmaceutical Co., Ltd., JIMRO Co., Ltd., Tanabe Mitsubishi Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Miyarisan Pharmaceutical Co., Ltd., and Zeria Pharmaceutical Co., Ltd. T.M. received service honoraria from Otsuka Pharmaceutical Co., Ltd. and Takeda Pharmaceutical Co., Ltd.
Funding Information:
This work was supported by a Grant-in-Aid for Scientific Research B (25293178, to H.S.) and a Grant-in-Aid for Challenging Exploratory Research (26670065, to H.S.) from the Japan Society for the Promotion of Science (JSPS); by a MEXT-Supported Program for the Strategic Research Foundation at Private Universities (S1411003, to H.S.); by Princess Takamatsu Cancer Research grants (13 -24513, to?H.S.); and by Keio Gijuku Academic Development Funds (to J.M. and H.S.).
Publisher Copyright:
© 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
PY - 2022
Y1 - 2022
N2 - Background and aim: The severity of atrophic gastritis is significantly associated with the risk of gastric cancer. Although the current gold standard for assessing the gastric cancer risk is esophagogastroduodenoscopy with a pathological examination, the development of less-invasive biomarkers is warranted for efficient risk stratification of gastric cancer. Serum pepsinogens (PGs) are biomarkers used to predict the extent of gastric mucosal atrophy; however, they are not an accurate reflection of gastric mucosal atrophy after Helicobacter pylori eradication. The present study was conducted to investigate the usefulness of plasma ghrelin levels as a marker for gastric mucosal atrophy, and as a risk stratification marker for gastric cancer, even after H. pylori eradication. Methods: Patients who received H. pylori eradication treatment were enrolled in the study. The severity of gastric mucosal atrophy was evaluated both endoscopically and histologically. Serum pepsinogen and plasma ghrelin levels were measured before and at 1, 12, 24, and 48 weeks after treatment. The study was approved by the Research Ethics Committee of the Keio University School of Medicine (no. 20140102; 8 July 2014). Results: Eighteen patients completed the study protocol. Total and acyl plasma ghrelin levels demonstrated no significant change from before treatment to 48 weeks after eradication; however, there was a significant difference between open-type and closed-type atrophic gastritis. The PG I/II ratio increased significantly from 48 weeks after H. pylori eradication. The severity of the histological intestinal metaplasia scores correlated inversely with plasma total ghrelin levels from before to 48 weeks after H. pylori eradication. Conclusion: Plasma levels of ghrelin correlate well with the level of gastric mucosal atrophy, even after H. pylori eradication.KEY MESSAGES Ghrelin plasma levels are associated with the progression of endoscopic atrophic gastritis, even at 48 weeks after H. pylori eradication. Ghrelin plasma levels are also associated with increased severity of histological intestinal metaplasia 48 weeks after H. pylori eradication. Pepsinogen I/II ratios increased immediately after H. pylori eradication and are inappropriate for assessing atrophic gastritis after H. pylori eradication.
AB - Background and aim: The severity of atrophic gastritis is significantly associated with the risk of gastric cancer. Although the current gold standard for assessing the gastric cancer risk is esophagogastroduodenoscopy with a pathological examination, the development of less-invasive biomarkers is warranted for efficient risk stratification of gastric cancer. Serum pepsinogens (PGs) are biomarkers used to predict the extent of gastric mucosal atrophy; however, they are not an accurate reflection of gastric mucosal atrophy after Helicobacter pylori eradication. The present study was conducted to investigate the usefulness of plasma ghrelin levels as a marker for gastric mucosal atrophy, and as a risk stratification marker for gastric cancer, even after H. pylori eradication. Methods: Patients who received H. pylori eradication treatment were enrolled in the study. The severity of gastric mucosal atrophy was evaluated both endoscopically and histologically. Serum pepsinogen and plasma ghrelin levels were measured before and at 1, 12, 24, and 48 weeks after treatment. The study was approved by the Research Ethics Committee of the Keio University School of Medicine (no. 20140102; 8 July 2014). Results: Eighteen patients completed the study protocol. Total and acyl plasma ghrelin levels demonstrated no significant change from before treatment to 48 weeks after eradication; however, there was a significant difference between open-type and closed-type atrophic gastritis. The PG I/II ratio increased significantly from 48 weeks after H. pylori eradication. The severity of the histological intestinal metaplasia scores correlated inversely with plasma total ghrelin levels from before to 48 weeks after H. pylori eradication. Conclusion: Plasma levels of ghrelin correlate well with the level of gastric mucosal atrophy, even after H. pylori eradication.KEY MESSAGES Ghrelin plasma levels are associated with the progression of endoscopic atrophic gastritis, even at 48 weeks after H. pylori eradication. Ghrelin plasma levels are also associated with increased severity of histological intestinal metaplasia 48 weeks after H. pylori eradication. Pepsinogen I/II ratios increased immediately after H. pylori eradication and are inappropriate for assessing atrophic gastritis after H. pylori eradication.
KW - Ghrelin
KW - atrophic gastritis
KW - gastric cancer
KW - intestinal metaplasia
KW - pepsinogen
UR - http://www.scopus.com/inward/record.url?scp=85122833851&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85122833851&partnerID=8YFLogxK
U2 - 10.1080/07853890.2021.2024875
DO - 10.1080/07853890.2021.2024875
M3 - Article
C2 - 35000515
AN - SCOPUS:85122833851
SN - 0785-3890
VL - 54
SP - 170
EP - 180
JO - Annales medicinae experimentalis et biologiae Fenniae
JF - Annales medicinae experimentalis et biologiae Fenniae
IS - 1
ER -